Drug development trajectory of anticancer drugs after initial pediatric-eligible trials.

Martin SD, Pitafi D, Bourgeois F, DuBois SG

DOI: 10.1002/cncr.70433
Published: 2026 May 1
Container: Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cncr.70433,
  title = {Drug development trajectory of anticancer drugs after initial pediatric-eligible trials.},
  author = {Martin SD and Pitafi D and Bourgeois F and DuBois SG},
  year = {2026},
  journal = {Cancer},
  doi = {10.1002/cncr.70433},
  url = {https://doi.org/10.1002/cncr.70433}
}

RIS

TY  - JOUR
TI  - Drug development trajectory of anticancer drugs after initial pediatric-eligible trials.
AU  - Martin SD
AU  - Pitafi D
AU  - Bourgeois F
AU  - DuBois SG
PY  - 2026
JO  - Cancer
DO  - 10.1002/cncr.70433
UR  - https://doi.org/10.1002/cncr.70433
ER  -

APA

SD, M., D, P., F, B., & SG, D. (2026). Drug development trajectory of anticancer drugs after initial pediatric-eligible trials.. Cancer. https://doi.org/10.1002/cncr.70433

Source records

pubmed · retrieved 2026-09-25T22:34:21.984Z